DOCSLIB.ORG

Loss of Heterozygosity Frequently Affects Chromosome 17Q in Non-Small Cell Lung Cancer1 Kumi M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Loss of Heterozygosity Frequently Affects Chromosome 17Q in Non-Small Cell Lung Cancer1 Kumi M [CANCER RESEARCH 55, 4268-4272, October 1, 1995] Advances in Brief Loss of Heterozygosity Frequently Affects Chromosome 17q in Non-Small Cell Lung Cancer1 kumi M. Fong,2 Yoshiki Kida, Paul V. Zimmerman, Makoto Ikenaga, and Peter J. Smith3 Queensland Canter Fund Research Unit, Department of Pathology. University of Queensland Medical School, Herston, Queensland. Australia 4006 ¡K.M. F., Y. K.. M. l.. P. J. S.J ami Department of Thoracic Medicine. The Prince Charles Hospital, Chermside, Queensland. Australia 4032 ¡K.M. F.. P. V. Z.] Abstract specific regions and can be independent of LOH at 17p and p53 mutations. Although the short arm of chromosome 17, which contains the p53 gene, is frequently affected by loss of heterozygosity (LOH) in lung cancer, Materials and Methods little is known about similar changes on the long arm. We found that LOH affected one or more of six loci along chromosome 17 in 59% of 102 DNA was obtained from 108 cases of postsurgically staged, resected informative non-small cell lung cancer (NSCLC) cases. Specifically, the NSCLC, and normal lung tissue from patients at The Prince Charles Hospital frequency of LOH at 17q was 42%, approaching that at 17p (54%), and (Brisbane, Australia) with fully informed consent as described previously (28). two distinct 17q regions were implicated. LOH at D17S4 on 17q was more Southern blot analysis of RFLPs was used to detect LOH at six loci along frequent in adcnocarcinomas than in squamous cell carcinomas, whereas chromosome 17 (Table 1), as reported previously (28). SSCP was used to squamous cell carcinomas had more LOH at 17p than at 17q, findings that screen exons 5-8 of the p53 gene (29). Statistical analysis was performed examining for differences between groups with x2 or Fisher's test, differences indicate molecular genetic heterogeneity between the major NSCLC sub types. In addition, LOH at 17q correlated with higher T stages and a between means with / tests, and Kaplan-Meier survival curves with log-rank significantly worse prognosis. In comparison. 25% of cases had mutations tests. Median follow-up duration was 23 months from time of analysis. of p53 exons 5-8 but these were not associated with stage or survival. The data suggest that independent ofp53, there are important tumor suppres Results sor gene(s) on 17q that may influence NSCLC pathogenesis, progression, Of the 108 cases analysed, 102 were heterozygous (informative) at and survival. one or more chromosome 17 loci. LOH involving either or both chromosomal arms affected 60 of the 102 (59%) informative NSCLC Introduction cases, with 54% showing LOH at 17p (D17S5) and 42% having LOH In Western countries, lung cancer is the leading cause of cancer at 17q (Table 1). The frequency of 17q LOH from centromere to deaths in males, with a similar pattern developing in females. Onco- telomere was: NFI, 20%; NM23-H1, 27%; D17S40, 34%; D17S21, genic activation and the inactivation of tumor suppressor genes by 42%; and DI7S4, 29% (Fig. 1). LOH was independent of preoperative mutation and allelic deletion are implicated in the pathogenesis of adjuvant treatment because it was not detected in the patients who cancers including NSCLC.4 received either radiotherapy (n = 4) or chemotherapy (;; = 1). Chromosome 17 appears to be an important target for such molec Two patterns of LOH were identified. In 11 cases, LOH was found ular abnormalities. At region pl3 is the p53 gene, a tumor suppressor at all informative markers, indicating that the whole of chromosome gene that is often disrupted in lung cancer (1). These changes include 17 was deleted. The other pattern was of LOH apparently restricted to frequent LOH at 17pl3 (2, 3) and specific p53 mutations in 23-52% one chromosomal arm. For instance, there were 16 cases with LOH at of resected NSCLC tumors (4-9) and 74% of cell lines (10). 17p but retained heterozygosity at 17q (another 2 cases had 17p LOH In addition, there is functional evidence of at least one other but were uninformative at all 17q markers). In contrast, LOH was chromosome 17 tumor suppressor gene from chromosomal transfer localized to the long arm in 17 cases (Table 2), with a distinct region studies (11). Candidate genes on 17q include NFÃŒ,NM23-H1 of loss implicated between, but excluding, D17S40 and DÃŒ7S2ÃŒ.In (AWE/), and NM23-H2 (NME2) antimetastatic genes, the prohibitin addition, another 17q region was suggested by case 115 to lie more proximally, centered around NM23-HI and flanked by NFÃŒand gene, and the familial breast/ovarian (BRCAI) locus. LOH affecting D17S40. multiple regions of 17q has been reported familial and sporadic breast p53 mutations at exons 5-8 were detected by mobility shift of (12-19), ovarian (18-23), esophageal (24), and head and neck (25), single-strand conformational polymorphism bands in 27 of 108 (25%) and certain cancers with a familial link (26). NSCLC cases, all of which were somatically acquired (data not In comparison, lung cancer has been much less studied, although a shown). There were 9, 5, 7, and 6 mutations detected at exons 5-8, single 17q marker was affected by LOH in 21% of 39 informative respectively. The clinico-pathological features are shown in Table 3, NSCLCs in Japanese patients (27). Here, we report that LOH occurs and one mutation (case 53) may have conceivably been due to frequently along chromosome 17q in resected NSCLC, targeting preoperative adjuvant chemotherapy. As expected, p53 mutations correlated with LOH at 17p, with LOH being found in 14 of 17 cases Received 7/13/95; accepled 8/17/95. compared with 23 of 51 cases without mutations (P = 0.008; )f), The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with implicating p53 as the responsible tumor suppressor gene on 17p. 18 U.S.C. Section 1734 solely to indicate this fact. However, as D17S5 is actually distal to p53, it should be noted that 1This study was supported by TPCH. the Queensland Cancer Fund, and by a NH and MRC (Australia) Medical Postgraduate Scholarship (K. F.). LOH here is also consistent with the presence of a more distal 17p - To whom requests for reprints should be addressed. tumor suppressor gene, as has been suggested in breast (12, 30) and 1 Present address: Department of Hematology and Oncology. Royal Children's ovarian cancers (31). Hospital, Fleminglon Road, Parkville. Victoria, Australia 3052. * The abbreviations used are: NSCLC. non-small cell lung cancer; SCC, squamous cell Comparing the two major histological subtypes. LOH at DI7S4 on carcinoma; LOH. loss of heterozygosity. 17q was more common in adenocarcinomas than in SCCs [13 (38%) 4268 Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1995 American Association for Cancer Research. LOH FREQUENTLY AFFECTS CHROMOSOME 17 IN NSCLC Table 1 Frequency of LOH on chromosome 17 in NSCLC No. of NSCLC cases with LOH/informative cases ( LocusDI7S5NFINM23-HID17S40D17S21D17S4RestrictionenzymeTat/lTai/\BjgfflMspUBptaMsp\IHpa\\Taq\Alíelesize(kb)VNTR"2.8/2.67.6/2.315.0/7.04.3/3.9VNTRProbepYNZ22AE25pNM23-HlpEWHllpC63pTHH59Location17pl3.317qll.217q21.3-2217ql2-2417q23-qtcr17q23-25.3Overallsubtypes37/68 cell17/28(61)1/13 (39)''7/22 (54)9/44 (20)13/49(27)12/35 (8)3/15 (32)*6/26 (23)''4/17 (20)3/10 (24)*6/17 (34)16/38(42)20/69 (30)6/15 (40)3/24(12)1 (36)*13/34(38)'20/44 (29)42/99 17qAll (42)Squantous 1/38 (29)Adcnocarcinomas12/31(45)* " VNTR. variable number of tandem repeats. ' P > 0.05 (Fisher's or \~ t£sOfor the difference in LOH between squamous cell carcinomas and adenocarcinomas. '' P < 0.05 (Fisher's or )f test) for the difference in LOH between squamous cell carcinomas and adcnocarcinomas. DJ7S5 NFJ NM23-HI D17S40 DJ7S2Õ D17S4 Fig. 1. Examples of LOH at chromosome 17 markers. Examples of LOH (arrows) at chromo some 17 loci (in each case, normal lung and tumor DNA is on the left and right, respectively). fri. of 34 versus 3 (12%) of 24] (P < 0.05; Fisher's test). The higher involvement than those without LOH [12 (54%) of 22 versus 4 (22%) frequency of LOH at D17S4 in adenocarcinomas could be explained of 18] (P < 0.05, x2). if there were a third tumor suppressor region specifically for adeno Because this data indicated an important gene(s) on chromosome carcinomas distally on 17q because D17S4 lies outside the common 17, the clinico-pathological significance of LOH on each chromo region of loss between DI7S40 and DI7S21. However, because somal arm and p53 mutations was examined. Although LOH at 17p another possibility is that adenocarcinomas have more extensive 17q correlated significantly with higher T-,_4 stages, neither it nor p53 LOH, detailed mapping is necessary to confirm whether such a region mutations were associated with tumors-nodes-metastasis stage (Table exists in adenocarcinomas. 3) or survival (P > 0.05; data not shown). In contrast, LOH at 17q not In contrast, SCCs had more frequent LOH at 17p than at 17q [17 only correlated with higher T stages (Table 3), but also with a worse (61%) of 28 versus 11 (29%) of 38] (P = 0.01, x2 test). Likewise, as survival (Fig. 2). In addition, distal 17q LOH in the adenocarcinoma reported previously (5), p53 mutations were also significantly more subtype also correlated with a poorer survival (P = 0.005 and common in SCCs than in adenocarcinomas [17 (40%) of 43 versus 5 P = 0.011 for the DJ7S21 and D17S4 markers, respectively). (11%) of 46] (P = 0.002, x2 test) and in males compared to females As expected, there were more smokers in group with LOH along [23 (30%) of 76 versus 4 (12%) of 32] (P = 0.052, x2).
Load more

Recommended publications
  • Datasheet: VMA00345KT Product Details
    Datasheet: VMA00345KT Description: NUCLEOSIDE DIPHOSPHATE KINASE A ANTIBODY WITH CONTROL LYSATE Specificity: NUCLEOSIDE DIPHOSPHATE KINASE A Format: Purified Product Type: PrecisionAb™ Monoclonal Isotype: IgG2b Quantity: 2 Westerns Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Species Cross Reacts with: Mouse, Rat Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation 20μl Mouse monoclonal antibody prepared by affinity chromatography on Protein G Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers Immunogen Recombinant human nucleoside diphosphate kinase A External Database Links UniProt: P15531 Related reagents Entrez Gene: 4830 NME1 Related reagents Synonyms NDPKA, NM23 Page 1 of 3 Specificity Mouse anti Human nucleoside diphosphate kinase A antibody recognizes nucleoside diphosphate kinase A, also known as NDP kinase A, granzyme A-activated DNase, metastasis inhibition factor nm23, non-metastatic cells 1 and tumor metastatic process-associated protein. The NME1 gene was identified because of its reduced mRNA transcript levels in highly metastatic cells.
    [Show full text]
  • Global Screening of Sentrin-Specific Protease Family Substrates in Sumoylation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.25.964072; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Global Screening of Sentrin-Specific Protease Family Substrates in SUMOylation Yunzhi Wang, 1, 4 Xiaohui Wu,1, 4 Rui Ge,1, 4 Lei Song, 2 Kai Li, 2 Sha Tian,1 Lili Cai, 1 Mingwei Liu, 2 Wenhao Shi, 2Guoying Yu, 3 Bei Zhen, 2 Yi Wang, 2 Fuchu He, 1, 2, * Jun Qin, 1, 2, * Chen Ding1, 2, * 1State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Zhongshan Hospital, Fudan University, Shanghai, 200432, China 2State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, 102206, China 3State Key Laboratory of Cell Differentiation and Regulation, College of Life Science, Henan Normal University, Xinxiang, Henan 453007 4Co-first author *Correspondence: [email protected] (C.D.); [email protected] (J.Q.); [email protected] (F.H.); Key Words 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.25.964072; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Posttranslational modification; SUMO; Sentrin/SUMO-specific proteases; Mass Spectrometry; Innate Immunity Abstract Post-translational modification of proteins by the addition of small ubiquitin-related modifier (SUMO) is a dynamic process, in which deSUMOylation is carried out by members of the Sentrin/SUMO-specific protease (SENP) family.
    [Show full text]
  • Identi Cation of Crucial Genes in Metastatic Osteosarcoma And
    Identication of crucial genes in metastatic osteosarcoma and prognostic biomarker in osteosarcoma patients Weihao Wang First Aliated Hospital of Shantou University Medical College Zhaoyong Liu First Aliated Hospital of Shantou University Medical College Weiqing Lu First Aliated Hospital of Shantou University Medical College Huancheng Guo First Aliated Hospital of Shantou University Medical College Chunbin Zhou First Aliated Hospital of Shantou University Medical College Youbin Lin First Aliated Hospital of Shantou University Medical College Hu Wang ( [email protected] ) the First Aliated Hospital of Shantou University Medical Collegethe First Aliated Hospital of Shantou University Medical Collegethe First Aliated Hospital of Shantou University Medical Collegethe First Aliated Hospital of Shantou University Med Research article Keywords: osteosarcoma, metastasis, crucial genes, prognostic biomarker Posted Date: July 22nd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-44119/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract Background Osteosarcoma is still a challenging cancer that poses a huge threat to human health worldwide, especially in young people. The aim of this study was to identify prognostic genes associated with neoplasm metastasis in osteosarcoma, and construct a prognostic nomogram to help the orthopedist to assess prognosis of osteosarcoma patients. Methods Gene expression and clinical information were extracted from the TARGET database. Differentially expressed genes (DEGs) associated with osteosarcoma metastasis were identied and subjected to GO functional and KEGG pathway enrichment analyses. Survival and Cox analyses were used to identify prognostic genes. Results First, 214 DEGs were identied as crucial genes associated with osteosarcoma metastasis.
    [Show full text]
  • The NDPK/NME Superfamily: State of the Art Mathieu Boissan1,2, Uwe Schlattner3 and Marie-Lise Lacombe1
    Laboratory Investigation (2018) 98, 164–174 © 2018 USCAP, Inc All rights reserved 0023-6837/18 EDITORIAL The NDPK/NME superfamily: state of the art Mathieu Boissan1,2, Uwe Schlattner3 and Marie-Lise Lacombe1 Nucleoside diphosphate kinases (NDPK) are nucleotide metabolism enzymes encoded by NME genes (also called NM23). Given the fact that not all NME-encoded proteins are catalytically active NDPKs and that NM23 generally refers to clinical studies on metastasis, we use here NME/NDPK to denote the proteins. Since their discovery in the 1950’s, NMEs/NDPKs have been shown to be involved in multiple physiological and pathological cellular processes, but the molecular mechanisms have not been fully determined. Recent progress in elucidating these underlying mechanisms has been presented by experts in the field at the 10th International Congress on the NDPK/NME/AWD protein family in October 2016 in Dubrovnik, Croatia, and is summarized in review articles or original research in this and an upcoming issue of Laboratory Investigation. Within this editorial, we discuss three major cellular processes that involve members of the multi-functional NME/NDPK family: (i) cancer and metastasis dissemination, (ii) membrane remodeling and nucleotide channeling, and iii) protein histidine phosphorylation. Laboratory Investigation (2018) 98, 164–174; doi:10.1038/labinvest.2017.137 ucleoside diphosphate kinases mitochondria (Lacombe et al, upcoming issue8). (NDPK) are nucleotide metabolism NME1, NME2, NME3, and NME4 form hexamers enzymes encoded by NME (also as the catalytically active form (Ćetković et al, next named NM23) genes. NDPKs are issue9). Group II is comprised of more divergent ubiquitous enzymes catalyzing the proteins sharing only 22 to 44% identity with Ntransfer of a phosphate from nucleoside group I enzymes and between each other.
    [Show full text]
  • Two Separate Functions of NME3 Critical for Cell Survival Underlie a Neurodegenerative Disorder
    Two separate functions of NME3 critical for cell survival underlie a neurodegenerative disorder Chih-Wei Chena, Hong-Ling Wanga, Ching-Wen Huangb, Chang-Yu Huangc, Wai Keong Lima, I-Chen Tua, Atmaja Koorapatia, Sung-Tsang Hsiehd, Hung-Wei Kand, Shiou-Ru Tzenge, Jung-Chi Liaof, Weng Man Chongf, Inna Naroditzkyg, Dvora Kidronh,i, Ayelet Eranj, Yousif Nijimk, Ella Selak, Hagit Baris Feldmanl, Limor Kalfonm, Hadas Raveh-Barakm, Tzipora C. Falik-Zaccaim,n, Orly Elpelego, Hanna Mandelm,p,1, and Zee-Fen Changa,q,1 aInstitute of Molecular Medicine, College of Medicine, National Taiwan University, 10002 Taipei, Taiwan; bDepartment of Medicine, College of Medicine, National Taiwan University, 10002 Taipei, Taiwan; cInstitute of Biochemistry and Molecular Biology, National Yang-Ming University, 11221 Taipei, Taiwan; dInstitute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, 10002 Taipei, Taiwan; eInstitute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, 10002 Taipei, Taiwan; fInstitute of Atomic and Molecular Sciences, Academia Sinica, 10617 Taipei, Taiwan; gDepartment of Pathology, Rambam Health Care Campus, 31096 Haifa, Israel; hDepartment of Pathology, Meir Hospital, 44100 Kfar Saba, Israel; iSackler School of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel; jDepartment of Radiology, Rambam Health Care Campus, 31096 Haifa, Israel; kPediatric and Neonatal Unit, Nazareth Hospital EMMS, 17639 Nazareth, Israel; lThe Genetics Institute, Rambam Health Care Campus, 31096 Haifa, Israel; mInstitute of Human Genetics, Galilee Medical Center, 22100 Nahariya, Israel; nThe Azrieli Faculty of Medicine, Bar Ilan University, 13100 Safed, Israel; oDepartment of Genetic and Metabolic Diseases, Hadassah Hebrew University Medical Center, 91120 Jerusalem, Israel; pMetabolic Unit, Technion Faculty of Medicine, Rambam Health Care Campus, 31096 Haifa, Israel; and qCenter of Precision Medicine, College of Medicine, National Taiwan University, 10002 Taipei, Taiwan Edited by Christopher K.
    [Show full text]
  • Differential Expression Gene Symbol Upregulated
    Table S1. 1658 differential expressed genes with P-value < 0.05 in myeloid dendritic cells patients with all ergies compared to healthy controls. Differential Gene Symbol Expression Upregulated KIAA1217, RP11-111M22.2, RP11-21M24.2, FAM221B, TRIM9, CNKSR3, LRIT3, (N=771) RP11-26J3.1, RP11-708J19.1, RPS3AP35, AC096574.4, RBPMS, JPH3, RASGRF1, RP11-118E18.4, TPPP, KCNJ9, ARMC12, TUBB8P7, KCND3, CTD-2083E4.4, SLCO5A1, EGLN3, NOS3, RPS3AP40, OR10A4, AC007551.2, RP11-110I1.12, ZNF732, RP4-800G7.3, RNFT2, SFXN2, SEPT5, UFSP1, KRT8P26, RP11- 634H22.1, RP11-357G3.1, CTC-487M23.5, RP11-804H8.6, ROPN1L, E2F2, RP11- 983P16.4, SOX12, KRTAP16-1, FAM188B, TTC28, CTB-66B24.1, PLS1, SHF, ESR1, SOCS2, MNS1, GPR55, RP11-1020A11.2, C4orf32, BHLHE22, RP11- 63E5.6, SIGLEC15, FGFBP3, AP000692.10, CTD-2357A8.3, RP1-102E24.6, ZC4H2, AC074367.1, WDR86-AS1, YPEL1, HOXB-AS1, RP3-522P13.2, OR7E47P, AC068039.4, NUDT8, IBA57, PPP1R3G, CACNB3, KB-1460A1.1, IQCJ-SCHIP1-AS1, CRHR2, CD27-AS1, RP11-368J22.2, MANSC4, FITM2, AC002467.7, RPS5P2, SNHG17, GCAT, C10orf91, CTB-61M7.1, ATP8A2P2, RP11-50E11.2, TFAP4, CTD-2060C23.1, MED9, RP11-583F2.1, GAPDHP62, RN7SL801P, CYB5RL, ALG14, IGLV5-52, AC106801.1, RP11-403A21.3, LAD1, EARS2, NEURL3, DUSP14, RP11-116K4.1, PKNOX1, RP11-248J23.5, ZNF730, PSMF1, PINLYP, HOXA10, PTMAP8, RNLS, NANOGP7, FOXD1, AIFM2, KCNJ14, AC114730.8, RP11-804H8.5, C1orf109, PANK1, RPL32P26, RP11- 528A10.2, KL, METTL21B, CTD-2186M15.1, UBE3D, SMARCA5-AS1, SCARF2, AC000003.2, AC013470.6, PEX10, LRP11, ACTBP14, RP11-93B14.5, MIR1182, LIMCH1, IFI27L1, FSTL3,
    [Show full text]
  • NME/NM23/NDPK and Histidine Phosphorylation
    International Journal of Molecular Sciences Review NME/NM23/NDPK and Histidine Phosphorylation Kevin Adam y , Jia Ning y, Jeffrey Reina y and Tony Hunter * Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA; [email protected] (K.A.); [email protected] (J.N.); [email protected] (J.R.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 17 June 2020; Accepted: 7 August 2020; Published: 14 August 2020 Abstract: The NME (Non-metastatic) family members, also known as NDPKs (nucleoside diphosphate kinases), were originally identified and studied for their nucleoside diphosphate kinase activities. This family of kinases is extremely well conserved through evolution, being found in prokaryotes and eukaryotes, but also diverges enough to create a range of complexity, with homologous members having distinct functions in cells. In addition to nucleoside diphosphate kinase activity, some family members are reported to possess protein-histidine kinase activity, which, because of the lability of phosphohistidine, has been difficult to study due to the experimental challenges and lack of molecular tools. However, over the past few years, new methods to investigate this unstable modification and histidine kinase activity have been reported and scientific interest in this area is growing rapidly. This review presents a global overview of our current knowledge of the NME family and histidine phosphorylation, highlighting the underappreciated protein-histidine kinase activity of NME family members, specifically in human cells. In parallel, information about the structural and functional aspects of the NME family, and the knowns and unknowns of histidine kinase involvement in cell signaling are summarized.
    [Show full text]
  • Targeting Altered Nme Heterooligomerization in Disease?
    www.impactjournals.com/oncotarget/ Oncotarget, 2018, Vol. 9, (No. 2), pp: 1492-1493 Editorial Targeting altered Nme heterooligomerization in disease? Issam H. Abu-Taha, Christiane Vettel and Thomas Wieland The enzymatic activity of nucleoside diphosphate bound to Gs, in end-stage heart failure Gi2 was found kinases (NDPK), which are encoded by members of predominantly in the complex. This switch has profound the nme gene family, has been discovered in the 1950s. consequences on the resulting signal transduction (Figure It removes the terminal phosphate from a nucleoside 1). An increased complex formation of Nme2/Nme3 triphosphate (NTP) and adds it to a nucleoside diphosphate with Gs increases cAMP formation and contractility. In (NDP) and thus it is important for nucleotide homeostasis contrast, if Gi2 is bound, cAMP formation is constitutively in every living cell. At least the four group I Nme proteins suppressed which is in accordance with the observations (Nme1 - Nme4) carry this enzymatic activity. Nme1 and from failing human hearts. Taken together, the data Nme2 are most abundant and ubiquitously expressed. showed that the composition and localization of G In the 1990s it became evident that enhanced cancer protein signaling complexes can change over time during metastasis was linked to reduced expression of Nme1. disease development and in response to altered Nme Metastasis, the colonization of distant sites by a tumor, heteroligomerization. is often more life threatening than the growth of the As Nme1 has also been shown to form primary tumor, which can be surgically removed in many heterooligomers at least with Nme2 [3], it is worthwhile cases.
    [Show full text]
  • Metastases Suppressor NME2 Associates with Telomere Ends And
    2554–2565 Nucleic Acids Research, 2012, Vol. 40, No. 6 Published online 1 December 2011 doi:10.1093/nar/gkr1109 Metastases suppressor NME2 associates with telomere ends and telomerase and reduces telomerase activity within cells Anirban Kar1, Dhurjhoti Saha1, Gunjan Purohit1, Ankita Singh1, Parveen Kumar2, Vinod Kumar Yadav2, Pankaj Kumar2, Ram Krishna Thakur1 and Shantanu Chowdhury1,2,* 1 2 Proteomics and Structural Biology Unit and G.N.R. Knowledge Centre for Genome Informatics, Institute of Downloaded from https://academic.oup.com/nar/article/40/6/2554/2409182 by guest on 01 October 2021 Genomics and Integrative Biology, CSIR, Mall Road, Delhi 110 007, India Received June 27, 2011; Revised November 4, 2011; Accepted November 5, 2011 ABSTRACT INTRODUCTION Analysis of chromatin-immunoprecipitation Eukaryotic chromosome ends are protected by nucleopro- followed by sequencing (ChIP-seq) usually disre- tein assemblies called telomeres that are critical for main- gards sequence reads that do not map within taining chromosome integrity. In humans, telomeres binding positions (peaks). Using an unbiased comprise double-stranded DNA having short-tandem repeats of 50-TTAGGG-30 that extend into single strand approach, we analysed all reads, both that G-rich overhang of 130–210 nt at the 30-end (1,2). mapped and ones that were not included as part Though the exact mechanism of how telomeres stabilize of peaks. ChIP-seq experiments were performed in chromosome ends is not well established, it is increasingly human lung adenocarcinoma and fibrosarcoma becoming evident that regulatory control of telomerase cells for the metastasis suppressor non-metastatic activation (and/or recruitment to telomere ends) involves 2 (NME2).
    [Show full text]
  • Metastasis Suppressor NME1 Directly Activates Transcription of the ALDOC Gene in Melanoma Cells
    Molecular Mechanisms Underlying the Metastasis Suppressor Activity of NME1 in Malignant Melanoma Item Type dissertation Authors Pamidimukkala, Nidhi Vela Publication Date 2019 Abstract Metastatic melanoma is exceedingly lethal and is responsible for the majority of skin cancer related deaths. Impactful research on melanoma metastasis is crucial to improving prognosis. The discovery of metastasis suppressor genes, genes that inhibit... Keywords ALDOC; NME1; Metastasis; Fructose-Bisphosphate Aldolase; Melanoma; Transcription, Genetic Download date 26/09/2021 16:56:05 Link to Item http://hdl.handle.net/10713/9611 Curriculum Vitae Nidhi V. Pamidimukkala [email protected] https://www.linkedin.com/in/nidhi-pamidimukkala Doctor of Philosophy, 2019 EDUCATION 2012-2019 Ph.D., Graduate Program in Molecular Medicine, Cancer Biology Tack University of Maryland School of Medicine – Baltimore, MD 2005-2009 B.S., Biological Sciences, Mellon College of Science Carnegie Mellon University - Pittsburgh, PA 2005-2009 Minor, Chemistry, Mellon College of Science Carnegie Mellon University - Pittsburgh, PA RESEARCH EXPERIENCE 2012-2019 Graduate Research Assistant, Mentor: David M. Kaetzel, Ph.D University of Maryland School of Medicine-Baltimore, MD 2009-2012 Biochemist-MBV Bioprocessing Group Merck & Co, Inc.-Union, NJ 2008-2008 Future Talent Intern-Drug Metabolism Group Merck & Co., Inc- Rahway, NJ 2007-2009 Undergraduate Research Assistant, Mentor: Gordon S. Rule, Ph.D Carnegie Mellon University-Pittsburgh, PA RESEARCH PUBLICATIONS Pamidimukkala, N.V , Leonard, M.K, Snyder, D., McCorkle, J.R., Kaetzel, D.M. (2018). Metastasis Suppressor NME1 Directly Activates Transcription of the ALDOC Gene in Melanoma Cells. Anticancer Research,38(11), 6059-6068. PMID: 30396920 Leonard, M.K, Novak, M., Snyder, D., Snow, G., Pamidimukkala, N.V , McCorkle, J.R., Yang, X.H., Kaetzel, D.M.
    [Show full text]
  • The Subcellular Localization and Oligomerization Preferences of NME1/NME2 Upon Radiation-Induced DNA Damage
    International Journal of Molecular Sciences Article The Subcellular Localization and Oligomerization Preferences of NME1/NME2 upon Radiation-Induced DNA Damage Martina Radi´c 1, Marko Šoštar 2, Igor Weber 2 , Helena Cetkovi´c´ 2, Neda Slade 1 and Maja Herak Bosnar 1,* 1 Division of Molecular Medicine, Ruđer Boškovi´cInstitute, Bijeniˇcka54, 10000 Zagreb, Croatia; [email protected] (M.R.); [email protected] (N.S.) 2 Division of Molecular Biology, Ruđer Boškovi´cInstitute, Bijeniˇcka54, 10000 Zagreb, Croatia; [email protected] (M.Š.); [email protected] (I.W.); [email protected] (H.C.)´ * Correspondence: [email protected]; Tel.: +385-1-456-0996 Received: 23 December 2019; Accepted: 26 March 2020; Published: 29 March 2020 Abstract: Nucleoside diphosphate kinases (NDPK/NME/Nm23) are enzymes composed of subunits NME1/NDPK A and NME2/NDPK B, responsible for the maintenance of the cellular (d)NTP pool and involved in other cellular processes, such as metastasis suppression and DNA damage repair. Although eukaryotic NDPKs are active only as hexamers, it is unclear whether other NME functions require the hexameric form, and how the isoenzyme composition varies in different cellular compartments. To examine the effect of DNA damage on intracellular localization of NME1 and NME2 and the composition of NME oligomers in the nucleus and the cytoplasm, we used live-cell imaging and the FRET/FLIM technique. We showed that exogenous NME1 and NME2 proteins co-localize in the cytoplasm of non-irradiated cells, and move simultaneously to the nucleus after gamma irradiation. The FRET/FLIM experiments imply that, after DNA damage, there is a slight shift in the homomer/heteromer balance between the nucleus and the cytoplasm.
    [Show full text]
  • Bioinformatics Analysis of the Target Gene of Fibroblast Growth Factor Receptor 3 in Bladder Cancer and Associated Molecular Mechanisms
    ONCOLOGY LETTERS 10: 543-549, 2015 Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms XING AI1*, ZHUO-MIN JIA1,2*, JUAN WANG3, GUI-PING DI1, XU ZHANG2, FENGLING SUN1, TONG ZANG1 and XIUMEI LIAO1 1Department of Urology, Military General Hospital of Beijing PLA, Beijing 100700; 2Department of Urology, Chinese PLA General Hospital, Beijing 100853; 3Department of Medicine, Military General Hospital of Beijing PLA, Beijing 100700, P.R. China Received August 4, 2014; Accepted April 24, 2015 DOI: 10.3892/ol.2015.3231 Abstract. The aim of the present study was to elucidate CCNB1 and H2AFZ were significantly associated with BC, the molecular mechanisms of fibroblast growth factor as determined by the protein-protein interaction network of receptor 3 (FGFR3) activation via overexpression or muta- DEGs and co-expressed genes. In conclusion, the present tion of the FGFR3 target gene in bladder cancer (BC). study revealed the involvement of FGFR3 in the regulation The transcription profile data GSE41035, which included of sterol biosynthesis and metabolism in the maintenance of 18 BC samples, containing 3 independent FGFR3 short BC; in addition, the present study provided a novel insight hairpin (sh)RNA, and 6 control samples, containing enhanced into the molecular mechanisms of FGFR3 in BC. These green fluorescent protein (EGFP) shRNA, were obtained results may therefore contribute to the theoretical guidance from the National Center of Biotechnology Information into the detection and therapy of BC. Gene Expression Omnibus database. The Limma package with multiple testing correction was used to identify differen- Introduction tially expressed genes (DEGs) between FGFR3 knockdown and control samples.
    [Show full text]